Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma

A trial update confirms improved survival for prophylactic elective nodal irradiation and addition of erlotinib to definitive chemoradiotherapy in oesophageal squamous cell carcinoma (ESCC). High tumour EGFR protein expression shows promise to identify those who will benefit from erlotinib. This rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Baxter, Mark A., Spender, Lindsay C., Petty, Russell D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686478/
https://www.ncbi.nlm.nih.gov/pubmed/32958821
http://dx.doi.org/10.1038/s41416-020-01057-3
_version_ 1783613336131207168
author Baxter, Mark A.
Spender, Lindsay C.
Petty, Russell D.
author_facet Baxter, Mark A.
Spender, Lindsay C.
Petty, Russell D.
author_sort Baxter, Mark A.
collection PubMed
description A trial update confirms improved survival for prophylactic elective nodal irradiation and addition of erlotinib to definitive chemoradiotherapy in oesophageal squamous cell carcinoma (ESCC). High tumour EGFR protein expression shows promise to identify those who will benefit from erlotinib. This represents therapeutic progress, and has wider relevance for precision medicine strategies in ESCC.
format Online
Article
Text
id pubmed-7686478
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76864782021-09-22 Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma Baxter, Mark A. Spender, Lindsay C. Petty, Russell D. Br J Cancer Editorial A trial update confirms improved survival for prophylactic elective nodal irradiation and addition of erlotinib to definitive chemoradiotherapy in oesophageal squamous cell carcinoma (ESCC). High tumour EGFR protein expression shows promise to identify those who will benefit from erlotinib. This represents therapeutic progress, and has wider relevance for precision medicine strategies in ESCC. Nature Publishing Group UK 2020-09-22 2020-11-24 /pmc/articles/PMC7686478/ /pubmed/32958821 http://dx.doi.org/10.1038/s41416-020-01057-3 Text en © Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Editorial
Baxter, Mark A.
Spender, Lindsay C.
Petty, Russell D.
Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma
title Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma
title_full Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma
title_fullStr Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma
title_full_unstemmed Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma
title_short Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma
title_sort combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686478/
https://www.ncbi.nlm.nih.gov/pubmed/32958821
http://dx.doi.org/10.1038/s41416-020-01057-3
work_keys_str_mv AT baxtermarka combiningprecisionmedicineandprophylaxisinoesophagealsquamouscellcarcinoma
AT spenderlindsayc combiningprecisionmedicineandprophylaxisinoesophagealsquamouscellcarcinoma
AT pettyrusselld combiningprecisionmedicineandprophylaxisinoesophagealsquamouscellcarcinoma

Ejemplares similares